ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for HIV patients with aggressive lymphoma: targeted drug combo shows promise
Disease control OngoingThis early-stage trial tests a new drug (ibrutinib) added to standard chemotherapy for HIV-positive people with a type of aggressive lymphoma. The goal is to find the safest dose and see if the combination can better control the cancer. About 46 participants are enrolled to help …
Matched conditions: ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New combo therapy aims to extend remission in elderly lymphoma patients
Disease control OngoingThis study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…
Matched conditions: ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Could adding lenalidomide boost lymphoma treatment?
Disease control OngoingThis study tested whether adding lenalidomide to standard chemoimmunotherapy (R-CHOP) helps people with newly diagnosed, advanced diffuse large B-cell lymphoma. About 349 participants received either R-CHOP alone or R-CHOP plus lenalidomide. The goal was to see if the combination…
Matched conditions: ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. About 50 adults will take part to find the best dose and see if the combination is safe and works better than standard …
Matched conditions: ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC